Canada Greenlights Public Reimbursement for Leqembi, Expanding Alzheimer’s Treatment Access
Event summary
- Canada's Drug Agency (CDA-AMC) issued a final positive recommendation for public reimbursement of Leqembi (lecanemab) for early Alzheimer’s disease.
- The recommendation follows a reconsideration and paves the way for negotiations through the pan-Canadian Pharmaceutical Alliance.
- Leqembi is already approved in 53 countries and under review in 6 others, with subcutaneous formulations in development.
- Over 770,000 Canadians live with dementia, a number projected to rise to 1.7 million by 2050.
- BioArctic, through its partnership with Eisai, stands to benefit from expanded market access in Canada.
The big picture
The CDA-AMC’s recommendation is a strategic win for BioArctic and Eisai, broadening Leqembi’s accessibility in a key market. This move aligns with global trends toward earlier intervention in Alzheimer’s disease, where Leqembi has shown efficacy in slowing cognitive decline. The approval also underscores the growing emphasis on public healthcare systems covering innovative but high-cost treatments for neurodegenerative diseases.
What we're watching
- Market Expansion
- Whether the positive recommendation will accelerate reimbursement decisions across Canada’s provinces and territories.
- Regulatory Dynamics
- The pace at which other countries may follow Canada’s lead in approving Leqembi for public reimbursement.
- Commercial Strategy
- How BioArctic and Eisai will leverage this approval to strengthen their position in the Alzheimer’s treatment market.